Company logo

RAPT - RAPT Therapeutics, Inc.

NASDAQ -> Healthcare -> Biotechnology
South San Francisco, United States
Type: Equity

RAPT price evolution
RAPT
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Current assets
Cash $47.48 $54.13 $50.16 $45.77
Short term investments $111.38 $130.64 $154.83 $185.86
Net receivables
Inventory
Total current assets $161.78 $187.14 $207.42 $234.59
Long term investments
Property, plant & equipment $7.68 $8.38 $9.07 $9.53
Goodwill & intangible assets
Total noncurrent assets $11.55 $12.58 $13.34 $13.74
Total investments $111.38 $130.64 $154.83 $185.86
Total assets $173.33 $199.72 $220.76 $248.33
Current liabilities
Accounts payable $5.18 $5.3 $2.69 $8.94
Deferred revenue
Short long term debt $2.45 $2.39 $2.33 $2.28
Total current liabilities $21.84 $21.85 $15.41 $21.61
Long term debt $4.46 $5.07 $5.67 $6.25
Total noncurrent liabilities $4.46 $5.07 $5.67 $6.25
Total debt $6.91 $7.46 $8 $8.53
Total liabilities $26.29 $26.92 $21.08 $27.86
Shareholders' equity
Retained earnings -$484.68 -$453.81 -$422.44 -$397.15
Other shareholder equity $0.1 -$0.12 -$0.18 $0.34
Total shareholder equity $147.03 $172.8 $199.68 $220.47
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $47.48 $38.95 $24.03 $24.92
Short term investments $111.38 $210.12 $165.63 $86.59
Net receivables
Inventory
Total current assets $161.78 $252.69 $192.97 $115.6
Long term investments
Property, plant & equipment $7.68 $9.48 $2.74 $2.98
Goodwill & intangible assets
Total noncurrent assets $11.55 $13.52 $5.66 $3.37
Total investments $111.38 $210.12 $165.63 $86.59
Total assets $173.33 $266.21 $198.64 $118.97
Current liabilities
Accounts payable $5.18 $3.37 $2 $2.38
Deferred revenue $1.53 $4.96
Short long term debt $2.45 $2.17
Total current liabilities $21.84 $14.22 $9.6 $11.74
Long term debt $4.46 $6.82
Total noncurrent liabilities $4.46 $6.82 $2.66 $3.05
Total debt $6.91 $8.99
Total liabilities $26.29 $21.04 $12.26 $14.79
Shareholders' equity
Retained earnings -$484.68 -$367.88 -$284.05 -$214.84
Other shareholder equity $0.1 -$0.03 -$0.21 -$0.18
Total shareholder equity $147.03 $245.17 $186.38 $104.18
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $26.76 $27.02 $21.64 $25.57
Selling, general & administrative $6.45 $6.9 $6.72 $5.99
Total operating expenses $33.22 $33.92 $28.36 $31.56
Operating income -$33.22 -$33.92 -$28.36 -$31.56
Income from continuing operations
EBIT -$30.88 -$31.37 -$25.28 -$29.27
Income tax expense
Interest expense
Net income
Net income -$30.88 -$31.37 -$25.28 -$29.27
Income (for common shares) -$30.88 -$31.37 -$25.28 -$29.27
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue $1.53 $3.81 $5.04
Cost of revenue
Gross Profit $1.53 $3.81 $5.04
Operating activities
Research & development $101 $67.08 $56.98 $45.48
Selling, general & administrative $26.06 $20.24 $16.04 $12.77
Total operating expenses $127.06 $87.32 $73.02 $58.26
Operating income -$127.06 -$85.8 -$69.21 -$53.21
Income from continuing operations
EBIT -$116.8 -$83.84 -$69.2 -$51.9
Income tax expense $0.99
Interest expense
Net income
Net income -$116.8 -$83.84 -$69.2 -$52.89
Income (for common shares) -$116.8 -$83.84 -$69.2 -$52.89
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Net income -$30.88 -$31.37 -$25.28 -$29.27
Operating activities
Depreciation $0.91 $0.91 $0.85 $0.88
Business acquisitions & disposals
Stock-based compensation $4.43 $4.33 $4.24 $4.09
Total cash flows from operations -$27.75 -$21.88 -$28.81 -$18.6
Investing activities
Capital expenditures -$0.07 -$0.07 -$0.23 -$0.76
Investments $20.71 $25.82 $32.67 $26.07
Total cash flows from investing $20.64 $25.75 $32.44 $25.31
Financing activities
Dividends paid
Sale and purchase of stock $0.46 $0.11 $0.77 $0.12
Net borrowings
Total cash flows from financing $0.46 $0.11 $0.77 $0.12
Effect of exchange rate
Change in cash and equivalents -$6.66 $3.97 $4.4 $6.82
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$116.8 -$83.84 -$69.2 -$52.89
Operating activities
Depreciation $3.55 $2.81 $1 $1.12
Business acquisitions & disposals
Stock-based compensation $17.09 $11.26 $9.95 $8.69
Total cash flows from operations -$97.05 -$70.77 -$61.03 -$40.49
Investing activities
Capital expenditures -$1.13 -$0.84 -$0.76 -$0.4
Investments $105.26 -$44.65 -$80.59 -$87.04
Total cash flows from investing $104.13 -$45.49 -$81.35 -$87.44
Financing activities
Dividends paid
Sale and purchase of stock $1.45 $131.18 $141.48 $75.46
Net borrowings
Total cash flows from financing $1.45 $131.18 $141.48 $75.46
Effect of exchange rate
Change in cash and equivalents $8.53 $14.92 -$0.89 -$52.47
Fundamentals
Market cap $275.19M
Enterprise value $234.61M
Shares outstanding 34.40M
Revenue $0.00
EBITDA -$113.25M
EBIT -$116.80M
Net Income -$116.80M
Revenue Q/Q N/A
Revenue Y/Y -100.00%
P/E ratio -2.36
EV/Sales N/A
EV/EBITDA -2.07
EV/EBIT -2.01
P/S ratio N/A
P/B ratio 1.87
Book/Share 4.27
Cash/Share 1.38
EPS -$3.40
ROA -55.48%
ROE -63.14%
Debt/Equity 0.18
Net debt/EBITDA 0.19
Current ratio 7.41
Quick ratio 7.41